Abstract |
The combination of 2-chlorodeoxyadenosine (2-CDA) and cytosine arabinoside ( Ara-C) has been shown to be effective in children with refractory Langerhans cell histiocytosis (LCH). We have treated 5 patients with recurrent LCH with 2-CDA/ Ara-C chemotherapy and closely followed immune and hematopoietic function. These patients display a decline in the absolute CD4, CD8, and natural killer cell number, decrease in the CD4/CD8 ratio. Septic events, including pneumocystis infection were present after most of the treatment courses (15/21). These data suggest that 2-CDA / Ara-C, should be considered in resistant and relapsed pediatric patients with LCH with high-risk multiorgan involvement. Consequent profound prolonged combined immune deficiency and myelosupression should be anticipated.
|
Authors | Nataly Apollonsky, Jeffrey M Lipton |
Journal | Journal of pediatric hematology/oncology
(J Pediatr Hematol Oncol)
Vol. 31
Issue 1
Pg. 53-6
(Jan 2009)
ISSN: 1536-3678 [Electronic] United States |
PMID | 19125089
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Child, Preschool
- Cladribine
(administration & dosage)
- Cytarabine
(administration & dosage)
- Histiocytosis, Langerhans-Cell
(diagnostic imaging, drug therapy)
- Humans
- Infant
- Infant, Newborn
- Infusions, Intravenous
- Radiography
- Recurrence
- Survival Rate
|